Filter Results :

Your search for Biopharma returned 213 reports

Sort by


Kythera Biopharmaceuticals, Inc. (KYTH) - Financial and Strategic SWOT Analysis Review

09 Jan 2015  |  Published by:  GlobalData
SummaryKythera Biopharmaceuticals, Inc. (Kythera) is a biopharmaceutical company. The company discovers, develops and commercializes prescription products for the aesthetic medicine market. Its pipeline product include ATX-101. Kythera’s ATX-101 is an injectable drug, which is currently in late stag...

$ 300.00

Read More

HanAll Biopharma Co., Ltd. (009420) - Financial and Strategic SWOT Analysis Review

09 Jan 2015  |  Published by:  GlobalData
SummaryHanAll Biopharma Co., Ltd. (HanAll) is a pharmaceutical company. The company’s activities include drug delivery, biotherapeutics, and small molecule discovery. Its research and development pipeline includes HL156Can, HL152B, HL156Fib, hanferon, HL036 topical TNF-alpha inhibitor, HL161 anti-Fc...

$ 300.00

Read More

Synageva BioPharma Corp. (GEVA) - Financial and Strategic SWOT Analysis Review

09 Jan 2015  |  Published by:  GlobalData
SummarySynageva BioPharma Corp. (Synageva) is a biopharmaceutical company. The company discovers, develops and delivers medicines for patients with rare disease and unmet medical needs. Its products include SBC-102, SBC-103, SBC-104, SBC-105, SBC-106 and SBC-238. Synageva’s SBC-102 is a recombinant ...

$ 300.00

Read More

RegeneRx Biopharmaceuticals, Inc. (RGRX) - Financial and Strategic SWOT Analysis Review

09 Jan 2015  |  Published by:  GlobalData
SummaryRegeneRx Biopharmaceuticals, Inc. (RegeneRx Biopharmaceuticals) is a biopharmaceutical company. The company designs, researches and develops peptides targeted at diseases with unmet medical needs. Its pharmaceuticals protect and repair tissue and organ damage caused by disease, trauma or othe...

$ 300.00

Read More

Synmosa Biopharma Corporation (4114) - Financial and Strategic SWOT Analysis Review

09 Jan 2015  |  Published by:  GlobalData
SummarySynmosa Biopharma Corporation (Synmosa) is a fully integrated specialty pharmaceutical company. It manufactures, markets and distributes ethical, over-the-counter (OTC) and healthcare products. It also produces non-pharmaceutical products such as cosmeceutical and nutrition products, and food...

$ 300.00

Read More

Sino Biopharmaceutical Limited (1177) - Financial and Strategic SWOT Analysis Review

09 Jan 2015  |  Published by:  GlobalData
SummarySino Biopharmaceutical Limited (Sino) is a pharmaceutical company. The company operates through Chinese Medicines and Chemical Medicines segment, Investment Segment, and Other Segments. Its Chinese medicines and chemical medicines segment manufactures, sells and distributes modernized Chinese...

$ 300.00

Read More

Integrated BioPharma, Inc. (INBP) - Financial and Strategic SWOT Analysis Review

09 Jan 2015  |  Published by:  GlobalData
SummaryIntegrated BioPharma, Inc. (IBI) is a biopharmaceutical company. The company develops and distributes nutritional supplement products and services. Its portfolio includes vitamin C, vitamin B12, acerola extract, vitamin E, ropufa, lycopene, acidulants, folic acid, emulsifiers, carotenoids, su...

$ 300.00

Read More

Sunshine Biopharma, Inc. (SBFM) - Financial and Strategic SWOT Analysis Review

09 Jan 2015  |  Published by:  GlobalData
SummarySunshine BioPharma, Inc. (Sunshine BioPharma) is a pharmaceutical company. The company conducts research, development and commercialization of drugs for the treatment of various forms of cancer. Its initial drug candidate is Adva-27a, which is a small molecule that has proven efficient agains...

$ 300.00

Read More

Provectus Biopharmaceuticals, Inc. (PVCT) - Financial and Strategic SWOT Analysis Review

09 Jan 2015  |  Published by:  GlobalData
SummaryProvectus Biopharmaceuticals, Inc. (Provectus) is a pharmaceutical company. The company develops and offers oncology therapies. Its products include PV-10 for melanoma, PH-10 for psoriasis, PH-10 for atopic dermatitis, PV-10 for metastatic liver cancer, PV-10 for recurrent breast cancer and P...

$ 300.00

Read More

Can-Fite BioPharma Ltd. (CFBI) - Financial and Strategic SWOT Analysis Review

09 Jan 2015  |  Published by:  GlobalData
SummaryCan-Fite BioPharma Ltd. (Can-Fite) is a biopharmaceutical company. It undertakes the discovery and clinical development of pharmaceutical products utilizing its platform technology. The company focuses on developing drugs that are used in the treatment of diseases such as cancer, sexual dysfu...

$ 300.00

Read More

ARCA biopharma, Inc. (ABIO) - Financial and Strategic SWOT Analysis Review

09 Jan 2015  |  Published by:  GlobalData
SummaryARCA biopharma, Inc. (ARCA biopharma) is a biopharmaceutical company. The company develops genetically-targeted therapies for the cardiovascular diseases. It focuses on develop personalized therapies for the treatment of cardiovascular disease through the use of genetics. ARCA biopharma’s pro...

$ 300.00

Read More

Galena Biopharma, Inc. (GALE) - Financial and Strategic SWOT Analysis Review

09 Jan 2015  |  Published by:  GlobalData
SummaryGalena Biopharma, Inc. (Galena) is a biotechnology company. The company discovers, develops and commercializes therapies for the treatment of unmet medical needs, and advance care. Its products include Abstral, NeuVax, NeuVax Herceptin, and folate binding protein. The company provides NeuVax ...

$ 300.00

Read More

XTL Biopharmaceuticals Ltd. (XTLB) - Financial and Strategic SWOT Analysis Review

09 Jan 2015  |  Published by:  GlobalData
SummaryXTL Biopharmaceuticals Ltd. (XTL) is a biopharmaceutical company. It carries out the acquisition and development of proprietary products. It focuses on the development of late stage pharmaceutical products in the areas of unmet clinical needs. The company has three product candidates such as ...

$ 300.00

Read More

RedHill Biopharma Ltd. (RDHL) - Financial and Strategic SWOT Analysis Review

09 Jan 2015  |  Published by:  GlobalData
SummaryRedHill Biopharma Ltd. (RedHill) is a biopharmaceutical company. It intends to acquire and develop late clinical-stage, proprietary drugs for the treatment of gastrointestinal and inflammatory conditions. The company’s product pipeline includes RP101, a proprietary, first-in-class, heat shock...

$ 300.00

Read More

Can-Fite BioPharma Ltd. - Product Pipeline Review - 2014

10 Dec 2014  |  Published by:  Global Markets Direct
Summary'Can-Fite BioPharma Ltd. - Product Pipeline Review - 2014’, provides an overview of the Can-Fite BioPharma Ltd.’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of Can-Fite BioPharma Ltd.’s, comple...

$ 1,500.00

Read More
Total 213 records.